Chronic Lymphocytic Leukemia Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Chronic Lymphocytic Leukemia Treatment Market by Drug Type (Targeted Drugs, Purine Analogues, Alkylating Agents, Corticosteroids, Other Drugs) and Cancer Type (B-cell Chronic Lymphocytic Leukemia, T-cell Chronic Lymphocytic Leukemia, Natural Killer Chronic Lymphocytic Leukemia), Route Of Administration (Parenteral, Oral, Others), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Chronic lymphocytic leukemia or β-cell chronic lymphocytic leukemia, which is the common type of leukemia of the WBC in adults. β-cell lymphocytes are a type of white blood cells, which produce in the bone marrow, develop in lymph nodes. These cells produce antibodies which fight against infection. In chronic lymphocytic leukemia, β-cells produce in an uncontrolled manner and accumulate in blood and bone marrow, and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, sometimes it occurs in the teenagers and children. Chronic lymphocytic leukemia is diagnosed by using complete blood count test, flow cytometry test, gene tests, and bone marrow tests. The global market for chronic lymphocytic leukemia treatment is expected to grow at a significant CAGR due to increase in the prevalence of chronic lymphocytic leukemia. According to WHO chronic lymphocytic leukemia is more prominent in the developed world such as North America and Europe due to genetic factors. The global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries, which is increased to 123,379 in 2010 and predicted to reach 282,683 new cases for 2020. The global chronic lymphocytic leukaemia treatment market is in developing stage in nature with several international players operating in the chronic lymphocytic leukemia treatment. Conventionally, chemo drugs are dominating the chronic lymphocytic leukemia treatment market. For instance, Rituximab, Imbruvica, and Idelalisib are the chemo drugs used in the treatment of chronic lymphocytic leukemia patients in combination or alone. Efficacy of these drugs in chronic lymphocytic leukemia is potentially replaced chemoimmunotherapy. Co-development and collaboration agreements are some of the key strategies adopted by some market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of chronic lymphocytic leukemia. Similarly, venetoclax by Roche, in collaboration with AbbVie, received approval from the US FDA for the treatment of chronic lymphocytic leukemia. With an increasing number of drug approvals, the chronic lymphocytic leukemia treatment market is anticipated to post a positive outlook over the forecast period.

Chronic Lymphocytic Leukemia Treatment Market

MARKET SUMMARY
-
x% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– x%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Chronic Lymphocytic Leukemia Treatment Market

  • The report on global chronic lymphocytic leukemia treatment market gives historical, current and future market sizes (US$ Mn) based on drug molecules, drug types, disease application, route of administration, end users, and geographic regions.
  • chronic lymphocytic leukemia treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Genzyme Corporation
  • Ono pharmaceuticals Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Arno Therapeutics Inc.
  •  Infinity Pharmaceuticals
  • Innate Pharma SA
  • AstraZeneca
  • Bellicum Pharmaceuticals Inc.
  • GlaxoSmithKline Plc
  • Novartis AG
Chronic Lymphocytic Leukemia Treatment Market

Drivers And Restraints

Increase in aging population, excessive exposure to carcinogenic chemicals, and genetical blood disorders are the major drivers for the growth of global market. Furthermore, growing disease awareness, and rising incidences of comorbidities may accelerates the growth of the market. Increased research and development in oncology sector, introduction of novel therapies, promising pipeline products, and new innovation in drug development helps in the growth of chronic lymphocytic leukemia treatment market. However, the high cost of the treatment for chronic lymphocytic leukemia and stringent regulatory policies might hamper the growth of global market over the forecast period.


North-America got significant share

Chronic Lymphocytic Leukemia Treatment Market

Geographically, the chronic lymphocytic leukemia treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. According to American Cancer Society, approximately 15,000 new cases has been observed every year for chronic lymphocytic leukaemia in the country. Chronic lymphocytic leukemia is more prominent in the developed countries like North America and Europe owing to unhealthy lifestyle and genetic factors. Increasing investment in research and development by drug developing firms, improving healthcare infrastructure in India, and China promoting the growth of chronic lymphocytic leukemia treatment market in Asia-Pacific region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments


Key

Report Outline

Chronic Lymphocytic Leukemia Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

  1. Executive summary
  2. Global Chronic Lymphocytic Leukemia Treatment Market Introduction
    • Global Chronic Lymphocytic Leukemia Treatment Market– Taxonomy
    • Global Chronic Lymphocytic Leukemia Treatment Market–Definitions
      • Drug Type
      • Cancer Type
  1. Global Chronic Lymphocytic Leukemia Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Chronic Lymphocytic Leukemia Treatment Market Dynamics – Factors Impact Analysis
    • Global Chronic Lymphocytic Leukemia Treatment Market– Regulations
      • US
      • Europe
      • Japan
    • Global Chronic Lymphocytic Leukemia Treatment Market– Recent Product Launches
  2. Global Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Chronic Lymphocytic Leukemia Treatment Market, By Drug Type, 2013 – 2017 and Forecast, 2018 – 2024
    • Targeted Drugs
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Purine Analogues
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Alkylating Agents
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Corticosteroids
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Cancer Type, 2013 – 2017 and Forecast, 2018 – 2024
    • B-cell Chronic Lymphocytic Leukemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • T-cell Chronic Lymphocytic Leukemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Natural Killer Chronic Lymphocytic Leukemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Region, 2018 – 2024
  2. North America Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Targeted Drugs
      • Purine Analogues
      • Alkylating Agents
      • Corticosteroids
      • Other Drugs
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • B-cell Chronic Lymphocytic Leukemia
      • T-cell Chronic Lymphocytic Leukemia
      • Natural Killer Chronic Lymphocytic Leukemia
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • North America Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends
  3. Europe Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Targeted Drugs
      • Purine Analogues
      • Alkylating Agents
      • Corticosteroids
      • Other Drugs
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • B-cell Chronic Lymphocytic Leukemia
      • T-cell Chronic Lymphocytic Leukemia
      • Natural Killer Chronic Lymphocytic Leukemia
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • Europe Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends
  4. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Targeted Drugs
      • Purine Analogues
      • Alkylating Agents
      • Corticosteroids
      • Other Drugs
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • B-cell Chronic Lymphocytic Leukemia
      • T-cell Chronic Lymphocytic Leukemia
      • Natural Killer Chronic Lymphocytic Leukemia
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
  • Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends
  1. Latin America Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Targeted Drugs
      • Purine Analogues
      • Alkylating Agents
      • Corticosteroids
      • Other Drugs
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • B-cell Chronic Lymphocytic Leukemia
      • T-cell Chronic Lymphocytic Leukemia
      • Natural Killer Chronic Lymphocytic Leukemia
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • Latin America Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends
  2. Middle East & Africa Chronic Lymphocytic Leukemia Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Targeted Drugs
      • Purine Analogues
      • Alkylating Agents
      • Corticosteroids
      • Other Drugs
    • Cancer Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • B-cell Chronic Lymphocytic Leukemia
      • T-cell Chronic Lymphocytic Leukemia
      • Natural Killer Chronic Lymphocytic Leukemia
    • Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index – By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2018 – 2024
    • MEA Chronic Lymphocytic Leukemia Treatment Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Genzyme Corporation (U.S.)
      • Ono pharmaceuticals Co. Ltd. (Japan)
      • Hoffmann-La Roche Ltd. (Switzerland)
      • AbbVie Inc. (U.S.)
      • Arno Therapeutics Inc. (U.S.)
      • Infinity Pharmaceuticals (U.S.)
      • Innate Pharma SA (France)
      • AstraZeneca (U.K.)
      • Bellicum Pharmaceuticals Inc. (U.S.)
      • GlaxoSmithKline Plc (U.K.)
      • Novartis AG (Switzerland)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • Genzyme Corporation (U.S.)
  • Ono pharmaceuticals Co. Ltd. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Arno Therapeutics Inc. (U.S.)
  • Infinity Pharmaceuticals (U.S.)
  • Innate Pharma SA (France)
  • AstraZeneca (U.K.)
  • Bellicum Pharmaceuticals Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Novartis AG (Switzerland)

Description

Chronic lymphocytic leukemia or β-cell chronic lymphocytic leukemia, which is the common type of leukemia of the WBC in adults. β-cell lymphocytes are a type of white blood cells, which produce in the bone marrow, develop in lymph nodes. These cells produce antibodies which fight against infection. In chronic lymphocytic leukemia, β-cells produce in an uncontrolled manner and accumulate in blood and bone marrow, and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, sometimes it occurs in the teenagers and children. Chronic lymphocytic leukemia is diagnosed by using complete blood count test, flow cytometry test, gene tests, and bone marrow tests. The global market for chronic lymphocytic leukemia treatment is expected to grow at a significant CAGR due to increase in the prevalence of chronic lymphocytic leukemia. According to WHO chronic lymphocytic leukemia is more prominent in the developed world such as North America and Europe due to genetic factors. The global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries, which is increased to 123,379 in 2010 and predicted to reach 282,683 new cases for 2020. The global chronic lymphocytic leukaemia treatment market is in developing stage in nature with several international players operating in the chronic lymphocytic leukemia treatment. Conventionally, chemo drugs are dominating the chronic lymphocytic leukemia treatment market. For instance, Rituximab, Imbruvica, and Idelalisib are the chemo drugs used in the treatment of chronic lymphocytic leukemia patients in combination or alone. Efficacy of these drugs in chronic lymphocytic leukemia is potentially replaced chemoimmunotherapy. Co-development and collaboration agreements are some of the key strategies adopted by some market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of chronic lymphocytic leukemia. Similarly, venetoclax by Roche, in collaboration with AbbVie, received approval from the US FDA for the treatment of chronic lymphocytic leukemia. With an increasing number of drug approvals, the chronic lymphocytic leukemia treatment market is anticipated to post a positive outlook over the forecast period.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX